[go: up one dir, main page]

NO942367D0 - - Google Patents

Info

Publication number
NO942367D0
NO942367D0 NO942367A NO942367A NO942367D0 NO 942367 D0 NO942367 D0 NO 942367D0 NO 942367 A NO942367 A NO 942367A NO 942367 A NO942367 A NO 942367A NO 942367 D0 NO942367 D0 NO 942367D0
Authority
NO
Norway
Prior art keywords
plasminogen
lys
reperfusion
plasmin
administration
Prior art date
Application number
NO942367A
Other languages
English (en)
Norwegian (no)
Other versions
NO942367L (no
Original Assignee
Immuno Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuno Ag filed Critical Immuno Ag
Publication of NO942367D0 publication Critical patent/NO942367D0/no
Publication of NO942367L publication Critical patent/NO942367L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • External Artificial Organs (AREA)
  • Farming Of Fish And Shellfish (AREA)
  • Electrotherapy Devices (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO942367A 1993-07-02 1994-06-21 Forhindring og behandling av ischemiske hendelser og reperfunsjonsskade resulterender derfra NO942367L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8803393A 1993-07-02 1993-07-02

Publications (2)

Publication Number Publication Date
NO942367D0 true NO942367D0 (ru) 1994-06-21
NO942367L NO942367L (no) 1995-01-03

Family

ID=22208925

Family Applications (1)

Application Number Title Priority Date Filing Date
NO942367A NO942367L (no) 1993-07-02 1994-06-21 Forhindring og behandling av ischemiske hendelser og reperfunsjonsskade resulterender derfra

Country Status (19)

Country Link
US (2) US5520912A (ru)
EP (1) EP0631786B1 (ru)
JP (1) JP2784146B2 (ru)
AT (2) AT407706B (ru)
AU (1) AU680492B2 (ru)
CA (1) CA2127199C (ru)
CZ (1) CZ283352B6 (ru)
DE (1) DE69411084T2 (ru)
DK (1) DK0631786T3 (ru)
ES (1) ES2119934T3 (ru)
GR (1) GR3027778T3 (ru)
HR (1) HRP940381B1 (ru)
HU (1) HU217961B (ru)
NO (1) NO942367L (ru)
PL (1) PL304061A1 (ru)
RU (1) RU2153353C2 (ru)
SI (1) SI0631786T1 (ru)
SK (1) SK281472B6 (ru)
ZA (1) ZA944522B (ru)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4411143C2 (de) * 1994-03-30 1996-08-01 Immuno Ag Thrombosemittel
EP1117437B1 (en) * 1998-09-29 2006-12-27 Leuven Research & Development vzw Use of compounds that reduce alpha2-antiplasmin in vivo for the preparation of a composition for the treatment of ischemic stroke
EP1062953A1 (en) * 1999-06-22 2000-12-27 Leuven Research & Development vzw Use of compounds that reduce alpha2-antiplasmin in vivo for the preparation of a composition for the treatment of ischemic stroke
US7184963B1 (en) 1999-01-19 2007-02-27 Bristol-Myers Squibb Company Method for determining care and prevention pathways for clinical management of wounds
AU778729B2 (en) * 1999-01-19 2004-12-16 Convatec Technologies Inc. Method for determining care and prevention pathways for clinical management of wounds
AU3173301A (en) * 2000-02-11 2001-08-20 European Molecular Biology Laboratory Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
DE10390418D2 (de) * 2002-02-06 2005-01-13 N Zyme Biotec Gmbh Verfahren zur Herstellung von rekombinanten Proteinen in Mikroorganismen
EP1545588A4 (en) * 2002-07-23 2007-12-05 Ludwig Inst Cancer Res METHOD AND COMPOSITIONS FOR THE ACTIVATION OR INHIBITION OF VEGF-D AND VEGF-C
PE20050438A1 (es) * 2003-10-20 2005-06-14 Esperion Therapeutics Inc Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos
WO2011004011A1 (en) 2009-07-10 2011-01-13 Thrombogenics Nv Variants of plasminogen and plasmin
WO2011023805A1 (en) 2009-08-28 2011-03-03 Thrombogenics N.V. Use of plasmin for the treatment of filtration failure after trabeculectomy
MX337248B (es) 2011-01-05 2016-02-19 Thrombogenics Nv Variantes de plasminogeno y plasmina.
CA2844644A1 (en) 2011-08-12 2013-02-21 Thrombogenics N.V. Plasminogen and plasmin variants
WO2013082458A1 (en) 2011-12-02 2013-06-06 The Regents Of The University Of California Reperfusion protection solution and uses thereof
US11478535B2 (en) 2016-12-15 2022-10-25 Talengen International Limited Method for preventing and treating fatty liver
WO2018107707A1 (zh) * 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种改善心脏病变的方法
TW201829448A (zh) 2016-12-15 2018-08-16 大陸商深圳瑞健生命科學硏究院有限公司 纖溶酶原在製備預防或治療肥胖症及疾病倂發的肥胖的藥物中的用途
CN110831668B (zh) * 2017-06-23 2024-04-12 普罗米蒂克生物治疗公司 与pai-1过表达相关的病状的血纤维蛋白溶酶原治疗
RU2729788C2 (ru) * 2018-09-04 2020-08-12 Федеральное государственное бюджетное учреждение науки "Федеральный исследовательский центр "Пущинский научный центр биологических исследований Российской академии наук" Средство, его применение и способ повышения устойчивости организма млекопитающих к ишемически-реперфузионному поражению тонкого кишечника
EP3914288A1 (en) 2019-01-24 2021-12-01 PreviPharma Consulting GmbH Plasminogen for treating and preventing microthrombosis
CN113677200B (zh) 2019-04-12 2023-09-26 乌格勒希研究有限公司 用于修复器官的方法和装置
CA3134900A1 (en) * 2019-04-12 2020-10-15 Uglk Science Ab Method and apparatus for reconditioning kidneys
CN114642722A (zh) * 2020-12-18 2022-06-21 四川大学华西医院 纤溶酶原用于制备促进血管新生的药物中的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3065190D1 (en) * 1979-11-05 1983-11-10 Beecham Group Plc Enzyme derivatives, and their preparation
JP2764264B2 (ja) * 1987-10-01 1998-06-11 株式会社ミドリ十字 線溶活性増強剤
US5084274A (en) * 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
US5256642A (en) * 1988-04-01 1993-10-26 The Johns Hopkins University Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
AT390801B (de) * 1988-07-28 1990-07-10 Immuno Ag Verfahren zur herstellung von lys-plasminogen
US5358936A (en) * 1990-08-03 1994-10-25 Paul Gordon Anionic furanose derivatives, methods of making and using the same
AT402367B (de) * 1990-10-11 1997-04-25 Immuno Ag Pharmazeutische zubereitung auf basis von lys-plasminogen

Also Published As

Publication number Publication date
PL304061A1 (en) 1995-01-09
EP0631786B1 (en) 1998-06-17
SK281472B6 (sk) 2001-04-09
CA2127199C (en) 2000-11-28
CA2127199A1 (en) 1995-01-03
ATA131094A (de) 2000-10-15
GR3027778T3 (en) 1998-11-30
SI0631786T1 (en) 1998-10-31
DE69411084D1 (de) 1998-07-23
DK0631786T3 (da) 1999-04-06
US5597800A (en) 1997-01-28
AU680492B2 (en) 1997-07-31
US5520912A (en) 1996-05-28
ZA944522B (en) 1995-02-23
ES2119934T3 (es) 1998-10-16
HRP940381A2 (en) 1997-04-30
HU9401983D0 (en) 1994-09-28
CZ283352B6 (cs) 1998-03-18
JP2784146B2 (ja) 1998-08-06
NO942367L (no) 1995-01-03
SK79894A3 (en) 1995-05-10
RU2153353C2 (ru) 2000-07-27
DE69411084T2 (de) 1998-12-03
RU94022754A (ru) 1996-08-10
JPH07145076A (ja) 1995-06-06
EP0631786A1 (en) 1995-01-04
HRP940381B1 (en) 1999-06-30
AU6485494A (en) 1995-01-12
HU217961B (hu) 2000-05-28
AT407706B (de) 2001-05-25
ATE167400T1 (de) 1998-07-15
HUT67225A (en) 1995-03-28
CZ161394A3 (en) 1995-01-18

Similar Documents

Publication Publication Date Title
NO942367D0 (ru)
GB9409281D0 (en) Transdermal device
NO885109D0 (no) FremgangsmŸte og middel for Ÿ forhindre blodpropp.
ES2182899T3 (es) Formulacion farmaceutica para la administracion subcutanea, intramuscular o intradermica de factor viii.
WO2002029087A3 (en) Use of lymphangiogenic agents to treat lymphatic disorders
NZ220260A (en) Synergistic combination of t-pa and sod and pharmaceutical formulation
GR3019328T3 (en) Vampire bat salivary Plasminogen activator vPA-alpha 1
RU94031618A (ru) Способ лечения кровоизлияний в мозг и устройство для его осуществления
DK0381640T3 (da) Thrombolytiske præparater
GR3005408T3 (ru)
DK532886A (da) Farmaceutisk praeparat med thrombolytisk aktivitet og fremgangsmaade til fremstilling deraf
Park et al. The clinical observation on 3 cases of hemifacial spasm
Zimmermann et al. Urokinase therapy of deep vein thrombosis of the lower limb
UA40717A (ru) Способ лечения больных с желудочным кровотечением

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application